Adverum Biotechnologies Inc ADVM

Healthcare Biotechnology

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. It also developing an early-stage pipeline of gene therapy programs.

NDAQ:ADVM - Post by User

Adverum Biotechnologies Inc

Bullboard Posts

Next >>

Post by whytestockson Jan 29, 2024 12:15pm

22 Views

Post# 35850628

Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Ch

NEWS: $ADVM Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific OfficerREDWOOD CITY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Romuald “Romu” Corbau, Ph.D., has j...ADVM - Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer

Bullboard Posts

Next >>

Nevada gold stock scores multiple high-grade hits